Plain-English translation of NCT06395844 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called METR-NK cells—immune cells taken from your own blood, grown in the lab with special nutrients to make them stronger, and then injected directly into your abdomen to fight ovarian cancer. The study wants to see if this treatment is safe and whether it helps shrink tumors in people with advanced ovarian cancer who either cannot have surgery or are too frail for surgery. About 28 people will participate.
Many women with advanced ovarian cancer cannot have surgery to remove all the cancer, either because the cancer is too spread out or because their health is too fragile. Doctors need new treatment options for these patients, and this medication uses the body's own immune system to attack cancer cells.
You likely qualify if…
You likely don't qualify if…
Your participation will involve having blood drawn to collect immune cells, which doctors will grow and strengthen in a lab over 14 days. Once ready, you will receive 4 rounds of treatment, each lasting 2 days, with 13 days between each round. Each treatment involves a slow infusion of the medication diluted in saline solution directly into your abdomen through a catheter. You will have blood and tissue samples taken before, during, and after treatment to help doctors understand how well the treatment is working and to monitor for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China